January 16, 2024—Gore & Associates announced that the first patients have been enrolled in the Gore VBX FORWARD clinical study.
The global prospective, multicenter, randomized controlled trial is comparing the company’s Viabahn VBX balloon expandable endoprosthesis—the VBX stent graft—versus bare metal stents (BMSs) for the treatment of patients with complex iliac occlusive disease. The company first announced the initiation of the trial in June 2023.